Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IN8bio (INAB)
NASDAQ:INAB
IN8bio (INAB) Stock Price & Analysis
119 Followers
INAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.65 - $3.48
Previous Close$1.02
Volume83.98K
Average Volume (3M)341.31K
Market Cap
$45.02M
Enterprise Value$36.52M
Total Cash (Recent Filing)$12.90M
Total Debt (Recent Filing)$5.26M
Price to Earnings (P/E)-1.0
Beta0.93
Next Earnings
May 10, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding43,287,325
10 Day Avg. Volume145,969
30 Day Avg. Volume341,310
Standard Deviation0.29
R-Squared0.00007
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$8.63Price Target Upside763.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
IN8bio News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsIN8bio's better competitive positioning in leukemia with more mature data and a clearly defined path towards a registration trial.
Financial ValuationIN8bio is undervalued in comparison to its peers, and the upcoming data update could significantly affect the stock's valuation.
Scientific DevelopmentsINB-300 platform's ability to differentiate and selectively target tumor cells over healthy cells may offer a wider therapeutic window and treat various types of cancer.
Bears Say
Efficacy ConcernsIn a recent study, 2 out of 3 patients relapsed after CAR T infusion, raising concerns about the treatment's efficacy.
Financial PerformanceFor 4Q23, the company reported no revenues and a net loss of $0.22 per share, compared to the consensus estimate of a net loss of $0.15 per share.
RisksRisks include clinical, regulatory, commercial, collaboration, financial, and intellectual property.
---
Ownership Overview
47.98% Insiders
1.62% Mutual Funds
5.10% Other Institutional Investors
45.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INAB FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was $0.65 and its highest was $3.48 in the past 12 months.
What is IN8bio’s market cap?
Currently, no data Available
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is May 10, 2024 which is in 5 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Mar 14, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.153 by -$0.067.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -$0.17.
How many shares outstanding does IN8bio have?
IN8bio has 43,287,327 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.153. Following the earnings report the stock price went down -1.724%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in INAB
---
IN8bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.63 (763.00% Upside)
$8.63 (763.00% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.88%
12-Months-Change
Fundamentals
Return on Equity
-125.90%
Trailing 12-Months
Asset Growth
2.03%
Trailing 12-Months
Company Description
IN8bio
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
---
INAB Stock 12 Months Forecast
Average Price Target
$8.63
▲(763.00% Upside)
Technical Analysis
Best Analysts Covering INAB
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-26.04%
reiterated a buy rating 25 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -26.04% per trade.
---